Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 2/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA5A | P35218 | 4/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17779170 | 1.00 | KMT2A (0.59) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL20254178 | 1.00 | KMT2A (0.59) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL107676 | 1.00 | KMT2A (0.59) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL12840944 | 1.00 | KMT2A (0.59) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL411430 | 1.00 | KMT2A (0.59) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL15492870 | 1.00 | KMT2A (0.59) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL27669444 | 0.86 | KMT2A (0.61) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL15681900 | 0.85 | KMT2A (0.56) | KMT2AALDH1A1MEN1LMNAMAPT | |
| Benzidine SCHEMBL29172643 | 0.85 | KMT2A (0.47) | KMT2AALDH1A1MEN1LMNAF2 | |
| SCHEMBL13761872 | 0.83 | KMT2A (0.58) | KMT2AALDH1A1MEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20160185815-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160176917-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160145296-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9156832-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2015-03-05 | — | — | US | disclosed |
| US-8815847-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | ANADYS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8765741-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140066396-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140031346-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8546602-B2 | 5,6-D hydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120302744-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8236948-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120130068-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8101800-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110229438-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110166344-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166344-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | KMT2A 3442/4885ALDH1A1 205/4885MEN1 195/4885 |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ACMSD, ACACA, ALDH1A1 | KMT2A 1745/4885ALDH1A1 3/4885MEN1 2439/4885 |
| US-20120302744-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | KMT2A 3442/4885ALDH1A1 205/4885MEN1 195/4885 |
| US-20160185815-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | KMT2A 4555/4885ALDH1A1 2372/4885MEN1 3979/4885 |
| US-20110229438-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | HAVCR2, ZC3HAV1, HCCS | KMT2A 3040/4885ALDH1A1 1468/4885MEN1 1917/4885 |
| US-20120130068-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | KMT2A 3442/4885ALDH1A1 205/4885MEN1 195/4885 |
| US-20140066396-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | HAVCR2, ZC3HAV1, HCCS | KMT2A 3040/4885ALDH1A1 1468/4885MEN1 1917/4885 |
| US-20140031346-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, CCR3, C5 | KMT2A 4392/4885ALDH1A1 786/4885MEN1 1595/4885 |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | THOP1, XDH, DUOX1 | KMT2A 2648/4885ALDH1A1 16/4885MEN1 1852/4885 |
| US-20160176917-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | GPBAR1, NR1H4, SLC10A1 | KMT2A 4555/4885ALDH1A1 2372/4885MEN1 3979/4885 |
| US-20160145296-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | KMT2A 4443/4885ALDH1A1 2549/4885MEN1 2705/4885 |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | KMT2A 4654/4885ALDH1A1 417/4885MEN1 2830/4885 |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | KMT2A 487/4885ALDH1A1 1542/4885MEN1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.